65,437 trials
Recurrent Thyroid Gland Carcinoma · Stage I Thyroid Gland Papillary Carcinoma · Stage II Thyroid Gland Papillary Carcinoma
Primary: Objective Response Rate (ORR) — 1 Participants
Clostridium Difficile Associated Disease
Primary: Percentage of Participants Reporting Prespecified Local Reactions Within 7 Days After Dose 1 (50- to 64-Year Age Cohort) — 16.7; 16.7; 50.0; 16.7 Percentage of…
Parkinson's Disease
Primary: Visual Sampling Parameter: Saccade Frequency During Gait — 0.48; 0.76; 0.67; 0.77 Saccade frequency (sacc/sec)
Multiple Sclerosis
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 93.8; 91.3; 94.4; 91.2 percentage of participants
Pneumococcal Disease
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 68; 5; 0; 1 participants
Acute Myeloid Leukemia
Primary: Recommended Phase II Dose (RP2D) of Ribavirin When Given in Combination With Low-dose Ara-C — 1400; 10 mg
Seroma · Wound Dehiscence · Wound Infection
Primary: Post-operative Seroma Formation — 16.9; 10.1 cm^3
Urinary Bladder, Overactive
Primary: Change From Baseline to End of Treatment (EoT) in Mean Volume Voided (MVV) Per Micturition — 13.4; 25.5; 6.9; 2.3 mL — p=0.046
Corneal Swelling
Primary: Central Corneal Swelling — 542.2; 542.4; 544.3 um
Diabetes · Diabetes Mellitus, Type 2
Primary: Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period — 353; 496 events — p=<0.0001
Severe Hepatic Veno-Occlusive Disease
Primary: Survival at Day+100 Following Hematopoietic Stem Cell Transplant — 38.2; 25.0 percentage of participants
Uncomplicated Plasmodium Falciparum Malaria
Primary: PCR-adjusted ACPR at Day 28 in the PP Population (All Patients) — 70.8; 68.4; 78.6 % ACPR PCR-adjusted
Orthostatic Intolerance
Primary: Orthostatic Tolerance — 634 mmHg*min
Healthy
Primary: Radlex Scale for Diagnostic Quality Ratings - 2D Images — 3.4093; 3.4179 units on a scale — p=0.920
Chronic Obstructive Pulmonary Disease
Primary: Mean Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) — 0.78; 0.71 AECOPD events/year — p=0.645